MDXH, BE0974461940

MDxHealth reports first-half growth. Nasdaq keeps a USD 1.00 bid test for MDxHealth stock

Published on 10/14/2026 at 06:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue hit USD 51.10 million in the first half of 2026, up 14.00 percent. Nasdaq's USD 1.00 bid rule applies to MDxHealth stock through December 28, 2026.

Financial and compliance markers

First-half revenue reached USD 51.10 million on September 30, 2026, up 14.00 percent.
The August 13, 2026 financing issued 44,052,862 shares for USD 20.00 million.
MDxHealth scheduled its next report for November 10, 2026.

MDXH, BE0974461940, Illustration mit AI erstellt.

MDxHealth (ISIN BE0974461940) reported first-half revenue of USD 51.10 million, up 14.00 percent, while a USD 1.00 Nasdaq bid requirement remained relevant on September 30, 2026, according to IT Boltwise. The combination puts revenue growth beside a wider operating loss and a defined compliance deadline.

What growth means for losses

Revenue from continuing operations rose 14.00 percent to USD 51.10 million in the first half of 2026. Over the same period, the operating loss widened from USD 6.20 million to USD 13.30 million, showing that sales growth has not yet translated into lower operating pressure.

Gross profit increased 7.00 percent to USD 32.60 million, but gross margin declined from 67.90 percent to 63.70 percent. That contrast is the central operating test for the next report because a lower margin can absorb part of the benefit from higher revenue.

Key events and figures

On August 13, 2026, MDxHealth placed 44,052,862 new shares at USD 0.45 per share and raised USD 20.00 million in gross proceeds, according to IT Boltwise. On August 28, 2026, the company had met Nasdaq's minimum market-value requirement, while the USD 1.00 minimum bid requirement remained open until December 28, 2026, the same report said. On September 30, 2026, the first-half figures showed revenue growth alongside a USD 13.30 million operating loss, according to IT Boltwise.

Next reporting date

IT Boltwise identified November 10, 2026 as the next scheduled reporting date. That date will give investors a fresh test of revenue progress, cash use and the effect of the August financing.

Compliance stays material

MDxHealth stock trades on NASDAQ under ticker MDXH, according to Tickertape. The company is classified in Healthcare and Diagnostics and Research, and its portfolio centers on precision tests for urologic care. The immediate investor question is whether the next report can show better operating leverage before the Nasdaq deadline.